Sanofi Stock Forecast for 2023 - 2025 - 2030
Updated on 04/23/2024
Sanofi Stock Forecast and Price Target
If the average 2024 price target of 108.00€ recently set by nine prominent experts for Sanofi is met, there would be a potential upside of approximately 22.49% from the last closing price in April, 2024. The high estimate is 125.00€, and the low is 80.00€. Even if you are not interested in SAN stock, you should be aware of its competitors and their current standings.
22.49% Upside
Sanofi Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Sanofi's Price has decreased from 74.77€ to 0.00€ – a 100.00% drop. For next year, the 21 analysts predict Fair Value of 103.61€, which would mean an increase of 100.00%. Over the next seven years, the pros' prediction is Fair Valueof 156.44€, which would mean a seven-year growth forecast of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$731.33 | Buy/Sell | $636.99 | 14.52% |
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$167.89 | Buy/Sell | $178.42 | 12.57% |
| AZN Stock Forecast | AstraZeneca PLC | Outperform |
17
|
£112.50 | Buy/Sell | £165.99 | 43.84% |
| ABT Stock Forecast | Abbott Laboratories | Outperform |
9
|
$107.07 | Buy/Sell | $118.92 | 18.61% |
| AMGN Stock Forecast | Amgen | Outperform |
4
|
$271.91 | Buy/Sell | $303.65 | 16.67% |
Sanofi Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Sanofi's Revenue has grown, increasing from 37.37€B to 46.44€B – an increase of 24.28%. For next year, the 13 analysts predict Revenue of 46.96€B, which would mean an increase of 1.11%. Over the next seven years, the pros' prediction is Revenueof 59.81€B, which would mean a seven-year growth forecast of 28.78%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BMY Stock Forecast | Bristol-Myers Squibb | Hold |
2
|
$49.14 | Buy/Sell | $58.15 | 11.93% |
| CSL Stock Forecast | CSL | Outperform |
12
|
$275.47 | Buy/Sell | $205.51 | -26.25% |
| CL Stock Forecast | Colgate-Palmolive Co | Outperform |
18
|
$88.33 | Buy/Sell | $88.97 | 5.29% |
.jpg)
Sanofi Dividend per Share Forecast for 2023 - 2025 - 2030
Sanofi's Dividend per Share has increased by 17.50% In the last three years, going from 3.20€ to 3.76€. In the next year, analysts expect Dividend per Share to reach 3.78€ – an increase of 0.53%. For the next seven years, the forecast is for Dividend per Share to grow by 24.47%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 4568 Stock Forecast | Daiichi Sankyo Company | Buy |
4
|
¥4.63k | Buy/Sell | ¥5.24k | 25.19% |
| 4519 Stock Forecast | Chugai Pharmaceutical | Outperform |
6
|
¥5.15k | Buy/Sell | ¥4.92k | 19.42% |
| BAS Stock Forecast | BASF | Outperform |
12
|
51.11€ | Buy/Sell | 49.50€ | 9.57% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ALC Stock Forecast | Alcon | Outperform |
8
|
CHF73.20 | Buy/Sell | CHF90.64 | 31.64% |
| CTVA Stock Forecast | Corteva | Outperform |
12
|
$55.20 | Buy/Sell | $61.72 | 15.94% |
| BEI Stock Forecast | Beiersdorf | Outperform |
17
|
136.40€ | Buy/Sell | 137.41€ | 9.24% |
Sanofi EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Sanofi's EBITDA has grown by 28.10%, from 10.47€B to 13.42€B. For the next year, analysts are expecting EBITDA to reach 14.31€B – an increase of 6.65%. Over the next seven years, experts predict that EBITDA will grow by 31.53%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| COLO B Stock Forecast | Coloplast A/S | Hold |
18
|
kr900.80 | Buy/Sell | kr812.28 | 1.02% |
| BIIB Stock Forecast | Biogen | Outperform |
10
|
$194.11 | Buy/Sell | $299.62 | 50.43% |
| BAYN Stock Forecast | Bayer | Hold |
5
|
27.32€ | Buy/Sell | 45.15€ | 17.13% |
Sanofi EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Sanofi's EBIT has grown from 7.59€B to 10.39€B – a 36.99% increase. Next year, analysts are expecting EBIT to reach 12.95€B – an increase of 24.63%. Over the next seven years, the forecast is for EBIT to grow by 87.80%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CHD Stock Forecast | Church & Dwight Co Inc | Hold |
11
|
$105.95 | Buy/Sell | $96.90 | -0.24% |
| ARGX Stock Forecast | argenx | Outperform |
4
|
337.10€ | Buy/Sell | 531.81€ | 30.23% |
| BNTX Stock Forecast | BioNTech | Outperform |
12
|
$88.01 | Buy/Sell | $123.75 | 14.24% |
Sanofi EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Sanofi's EPS has decreased from 5.86€ to 0.00€ – a 100.00% drop. For next year, the 21 analysts predict EPS of 8.12€, which would mean an increase of 100.00%. Over the next seven years, the pros' prediction is EPSof 12.26€, which would mean a seven-year growth forecast of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BAX Stock Forecast | Baxter International Inc | Outperform |
17
|
$40.40 | Buy/Sell | $44.86 | 11.39% |
| ALNY Stock Forecast | Alnylam Pharmaceuticals Inc | Outperform |
7
|
$145.79 | Buy/Sell | $245.24 | 47.47% |
| BMRN Stock Forecast | BioMarin Pharmaceutical | Outperform |
10
|
$89.49 | Buy/Sell | $111.56 | 22.36% |
.jpg)